AdultPediatricGeriatricDosage Forms & Strengths tablet, immediate release 25mg 50mg 100mg 200mg 300mg 400mg tablet, extended release 50mg 150mg 200mg 300mg 400mg Schizophrenia Immediate release Day 1: 50 mg/day PO divided q12hr Days 2-3: Dose increased daily in increments of 25-50 mg q8-12hr to 300-400 mg by day 4; further adjustments can be made in increments of 25-50 mg q12hr at intervals ≥2 days Dosage range: 150-750 mg/day Extended release Day 1: 300 mg/day PO; subsequently, may be increased by up to 300 mg/day at intervals ≥1 day Maintenance (monotherapy): 400-800 mg/day Patients who have discontinued therapy for >1 week should have their dose retitrated following initiation of therapy; patients may reinitiate at their previous maintenance dose if discontinued therapy <1 week Bipolar I Disorder, Mania Administered as monotherapy or as adjunct to lithium or divalproex Immediate release Day 1: 100 mg/day PO divided q12hr Day 2: 200 mg/day PO divided q12hr Day 3: 300 mg/day PO divided q12hr Day 4: 400 mg/day PO divided q12hr Further dosage adjustments, up to 800 mg/day by day 6, should be in increments ≤200 mg/day Dosage range: 400-800 mg/day; not to exceed 800 mg/day Extended release Day 1: 300 mg PO once daily Day 2: 600 mg PO once daily Maintenance (day 3 onward): 400-800 mg/day PO Bipolar Disorder, Depressive Episodes Either immediate-release or extended-release tablets may be given; dosage titrated upward over 4 days Day 1: 50 mg PO at bedtime Day 2: 100 mg PO at bedtime Day 3: 200 mg PO at bedtime Maintenance (day 4 onward): 300 mg PO at bedtime Bipolar I Disorder, Maintenance Administered as adjunct to lithium or divalproex Immediate release: 400-800 mg/day PO divided q12hr Extended release: 400-800 mg/day PO in single dose Generally, in maintenance phase, patients continue to receive same dosage on which they were stabilized Major Depressive Disorder Extended-release formulation administered as adjunct to antidepressants Days 1 and 2: 50 mg PO in evening Day 3: May be increased to 150 mg PO in evening Dosage range: 150-300 mg/day Alcohol Dependence (Off-label) 25-50 mg PO at bedtime; may be titrated; not to exceed 300 mg Insomnia (Off-label) Usually, 25 mg/day PO at bedtime initially Administration Preferably, take in evening without food or with light meal Switching from immediate release to extended release Convert to extended release tablets at equivalent immediate release total daily dose; administer once daily; individual adjustments may be necessary Dosage Forms & Strengths tablet, immediate release 25mg 50mg 100mg 200mg 300mg 400mg tablet, extended release 50mg 150mg 200mg 300mg 400mg Schizophrenia <12 years Safety and efficacy not established >12 years (monotherapy, immediate release) Day 1: 50 mg/day PO divided q12hr Day 2: 100 mg/day PO divided q12hr Day 3: 200 mg/day PO divided q12hr Day 4: 300 mg/day PO divided q12hr Day 5: 400 mg/day PO divided q12hr; further adjustments should be in increments ≤100 mg/day Dosage range: 400-800 mg/day Depending on response and tolerance, daily dose may be divided q8hr >12 years (monotherapy, extended release) Day 1: 50 mg/day PO once daily Day 2: 100 mg/day PO once daily Day 3: 200 mg/day PO once daily Day 4: 300 mg/day PO once daily Day 5: 400 mg/day PO once daily; further adjustments should be in increments ≤100 mg/day Bipolar I Disorder, Mania <10 years Safety and efficacy not established >10 years (monotherapy, immediate release) Day 1: 50 mg/day PO divided q12hr Day 2: 100 mg/day PO divided q12hr Day 3: 200 mg/day PO divided q12hr Day 4: 300 mg/day PO divided q12hr Day 5: 400 mg/day PO divided q12hr; further adjustments should be in increments ≤100 mg/day Dosage range: 400-600 mg/day Depending on response and tolerance, daily dose may be divided q8hr >10 years (monotherapy, extended release) Day 1: 50 mg/day PO once daily Day 2: 100 mg/day PO once daily Day 3: 200 mg/day PO once daily Day 4: 300 mg/day PO once daily Day 5: 400 mg/day PO once daily; further adjustments should be in increments ≤100 mg/day Dosage range: 400-600 mg once daily Not approved for dementia-related psychosis, because of increased risk of cardiovascular or infectious related deaths (see Black Box Warnings) Schizophrenia, Bipolar Disorder Immediate release: 50-200 mg/day PO; may be increased by 25-50 mg/day Extended release: 50 mg/day PO; may be increased by 50 mg/day Psychosis, Agitation Related to Alzheimer Dementia (Off-label) 12.5-50 mg/day PO initially; may be gradually increased as tolerated; not to exceed 200-300 mg/dayInteraction CheckerEnter a drug name and quetiapineNo Results No Interactions Found Interactions FoundContraindicatedSerious - Use AlternativeSignificant - Monitor CloselyMinorAll Interactions Sort By: SeverityName Contraindicated (4)amisulprideamisulpride, quetiapine. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndromeIncreases risk of neuroleptic malignant syndrome.goserelingoserelin increases toxicity of quetiapine by QTc interval. Contraindicated. Increases risk of torsades de pointes.lefamulinlefamulin will increase the level or effect of quetiapine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Lefamulin is contraindicated with CYP3A substrates know to prolong the QT interval.leuprolideleuprolide increases toxicity of quetiapine by QTc interval. Contraindicated. Increases risk of torsades de pointes.Serious - Use Alternative (103)abametapirabametapir will increase the level or effect of quetiapine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. For 2 weeks after abametapir application, avoid taking drugs that are CYP3A4 substrates. If not feasible, avoid use of abametapir.adagrasibadagrasib, quetiapine. Either increases effects of the other by QTc interval. Avoid or Use Alternate Drug. Each drug prolongs the QTc interval, which may increased the risk of Torsade de pointes, other serious arryhthmias, and sudden death. If coadministration unavoidable, more frequent monitoring is recommended for such patients.alfuzosinalfuzosin and quetiapine both increase QTc interval. Avoid or Use Alternate Drug.amisulprideamisulpride and quetiapine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.anagrelideanagrelide and quetiapine both increase QTc interval. Avoid or Use Alternate Drug.apalutamideapalutamide will decrease the level or effect of quetiapine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of apalutamide, a strong CYP3A4 inducer, with drugs that are CYP3A4 substrates can result in lower exposure to these medications. Avoid or substitute another drug for these medications when possible. Evaluate for loss of therapeutic effect if medication must be coadministered. Adjust dose according to prescribing information if needed.apomorphinequetiapine decreases effects of apomorphine by pharmacodynamic antagonism. Avoid or Use Alternate Drug.aripiprazolearipiprazole and quetiapine both increase QTc interval. Avoid or Use Alternate Drug.artemetherartemether and quetiapine both increase QTc interval. Avoid or Use Alternate Drug.atazanaviratazanavir increases levels of quetiapine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Consider alternative anti-HCV therapy to avoid increases in quetiapine exposures; if coadministration is necessary, reduce quetiapine dose to 1/6th of current dose and monitor for quetiapine associated adverse reactions; refer to quetiapine prescribing information for recommendations on adverse reaction monitoring.atomoxetineatomoxetine and quetiapine both increase QTc interval. Avoid or Use Alternate Drug.benzhydrocodone/acetaminophenbenzhydrocodone/acetaminophen, quetiapine. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.benzhydrocodone/acetaminophen and quetiapine both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequatebromocriptinequetiapine decreases effects of bromocriptine by pharmacodynamic antagonism. Avoid or Use Alternate Drug.buprenorphinebuprenorphine and quetiapine both increase QTc interval. Avoid or Use Alternate Drug.buprenorphine buccalbuprenorphine buccal and quetiapine both increase QTc interval. Avoid or Use Alternate Drug.buprenorphine subdermal implantbuprenorphine subdermal implant and quetiapine both increase QTc interval. Avoid or Use Alternate Drug.buprenorphine subdermal implant and quetiapine both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequatebuprenorphine transdermalbuprenorphine transdermal and quetiapine both increase QTc interval. Avoid or Use Alternate Drug.buprenorphine transdermal and quetiapine both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequatebuprenorphine, long-acting injectionbuprenorphine, long-acting injection and quetiapine both increase QTc interval. Avoid or Use Alternate Drug.buprenorphine, long-acting injection and quetiapine both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequatecabergolinequetiapine decreases effects of cabergoline by pharmacodynamic antagonism. Contraindicated.calcium/magnesium/potassium/sodium oxybatesquetiapine, calcium/magnesium/potassium/sodium oxybates. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.carbamazepinecarbamazepine will decrease the level or effect of quetiapine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.ceritinibceritinib and quetiapine both increase QTc interval. Avoid or Use Alternate Drug.ceritinib will increase the level or effect of quetiapine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.chloramphenicolchloramphenicol will increase the level or effect of quetiapine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.cimetidinecimetidine will increase the level or effect of quetiapine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.clarithromycinclarithromycin will increase the level or effect of quetiapine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.clozapineclozapine and quetiapine both increase QTc interval. Avoid or Use Alternate Drug.cobicistatcobicistat increases levels of quetiapine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration with atazanavir and cobicistat in patients taking quetiapine. If coadministration is necessary, reduce quetiapine dose to one-sixth of the current dose and monitor for quetiapine-associated adverse reactions. Refer to quetiapine prescribing information for initial dosing and titration of quetiapine.crizotinibcrizotinib and quetiapine both increase QTc interval. Avoid or Use Alternate Drug.dabrafenibdabrafenib will decrease the level or effect of quetiapine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.desfluranedesflurane and quetiapine both increase QTc interval. Avoid or Use Alternate Drug.donepezildonepezil and quetiapine both increase QTc interval. Avoid or Use Alternate Drug.dopaminequetiapine decreases effects of dopamine by pharmacodynamic antagonism. Contraindicated.efavirenzefavirenz and quetiapine both increase QTc interval. Avoid or Use Alternate Drug.eliglustateliglustat and quetiapine both increase QTc interval. Avoid or Use Alternate Drug.elvitegravir/cobicistat/emtricitabine/tenofovir DFelvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of quetiapine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration with quetiapine. If coadministration is necessary, reduce quetiapine dose to one-sixth of the current dose.encorafenibencorafenib and quetiapine both increase QTc interval. Avoid or Use Alternate Drug. Encorafenib is associated with dose-dependent QTc interval prolongation. Avoid with drugs known to prolong QT interval.entrectinibquetiapine and entrectinib both increase QTc interval. Avoid or Use Alternate Drug.enzalutamideenzalutamide will decrease the level or effect of quetiapine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.eribulineribulin and quetiapine both increase QTc interval. Avoid or Use Alternate Drug.erythromycin baseerythromycin base will increase the level or effect of quetiapine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.erythromycin ethylsuccinateerythromycin ethylsuccinate will increase the level or effect of quetiapine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.erythromycin lactobionateerythromycin lactobionate will increase the level or effect of quetiapine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.erythromycin stearateerythromycin stearate will increase the level or effect of quetiapine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.escitalopramescitalopram increases toxicity of quetiapine by QTc interval. Avoid or Use Alternate Drug.fexinidazolefexinidazole and quetiapine both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels and/or prolong QT interval.fexinidazole will increase the level or effect of quetiapine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Fexinidazole inhibits CYP3A4. Coadministration may increase risk for adverse effects of CYP3A4 substrates.fingolimodfingolimod and quetiapine both increase QTc interval. Avoid or Use Alternate Drug.gilteritinibgilteritinib and quetiapine both increase QTc interval. Avoid or Use Alternate Drug.glasdegibquetiapine and glasdegib both increase QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, monitor for increased risk of QTc interval prolongation.granisetrongranisetron and quetiapine both increase QTc interval. Avoid or Use Alternate Drug.histrelinhistrelin increases toxicity of quetiapine by QTc interval. Avoid or Use Alternate Drug. Increases risk of torsades de pointes.hydrocodonehydrocodone, quetiapine. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom